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ABSTRACT
Background: Combination therapy with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) in
a single inhaler is the mainstay of asthma management and salmeterolfluticasone combination (SFC) and
fixed-dose formoterolbudesonide combination (FBC) are currently available in Japan; however, there is noth-
ing to choose between the two. The purpose of this study was to clarify the effect of switching from SFC to FBC
in patients with asthma not adequately controlled under the former treatment regimen.
Methods: This was a prospective, multicenter, open-label, uncontrolled longitudinal study in 87 adult patients
with an Asthma Control Questionnaire, 5-item version (ACQ5) score of greater than 0.75 under treatment with
SFC 50250 μg one inhalation twice daily (bid). SFC was switched to FBC 4.5160 μg two inhalations bid.
Study outcomes included ACQ5 score, peak expiratory flow (PEF), FEV1, and fractional exhaled nitric oxide
(FeNO) at the end of treatment period.
Results: Eighty-three patients completed the study. ACQ5 scores improved and exceeded the clinically mean-
ingful difference after 12 weeks of treatment and well-controlled asthma (ACQ5 score0.75) was attained in 37
(44.6%) patients. Minimum and maximum PEF and FEV1 values improved significantly, but not FeNO values,
after switching from SFC to FBC.
Conclusions: Switching ICSLABA combination therapy is a useful option in the management of asthma that
is not optimally controlled.
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INTRODUCTION
The Japanese Guideline for Adult Asthma as well as
the Global Initiative for Asthma (GINA) recommend
the use of an inhaled corticosteroid (ICS) in combina-
tion with a long-acting β2-agonist (LABA) for patients
with asthma not adequately controlled with low- to
medium-dose ICS monotherapy.1,2 Combination prod-
ucts, containing both an ICS and a LABA in a single
inhaler, have been available in Japan in recent years
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Fig.　1　Study design. ACQ5, Asthma Control Question-
naire, 5-item version; FeNO, fractional exhaled nitric oxide; 
FBC, formoterol/budesonide combination; PEF, peak expira-
tory fl ow; SFC, salmeterol/fl uticasone combination.
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and may help to improve patient acceptability and ad-
herence in terms of taking both medications at the
same time: salmeterolfluticasone combination (SFC;
AdoairⓇ) and formoterolbudesonide combination
(FBC; SymbicortⓇ). These two combination products
have different properties, including inhalation de-
vices, onset of bronchodilatory action,3 and particle
size4,5; however, it is uncertain which of these medi-
cations to choose for each patient.
Previous studies have compared the efficacy of
these combination products directly, a fixed-dose of
SFC 100500 μg per day versus a fixed-dose of FBC
18640 μg per day, and shown controversial results.
The EXCEL study showed that both regimens signifi-
cantly improved asthma symptoms and lung function
but SFC was found to be significantly superior to
FBC in reducing the rate of moderatesevere exacer-
bations.6 In contrast, the COMPASS study demon-
strated that, compared with SFC, FBC significantly
reduced the risk of hospitalizationsemergency-room
visits by 28%.7 Since only fixed-dose use of each com-
bination therapy is currently approved in Japan, there
is nothing to choose between the two. Also, switching
treatment regimens is sometimes necessary in a real
clinical setting; however, very few studies have exam-
ined this.
In this prospective, multicenter, open-label, uncon-
trolled longitudinal study we evaluated the effective-
ness of switching between the medium dose of ICS
LABA combinations, from SFC delivered via Diskus
50250 μg one inhalation twice daily (bid) to FBC de-
livered via Turbuhaler 4.5160 μg two inhalations bid
in improving symptoms, pulmonary functions and air-
way inflammation in terms of the fractional exhaled
nitric oxide (FeNO) over a 12-week study period in
patients with asthma not adequately controlled under
the former treatment regimen.
METHODS
SUBJECTS
Patients with asthma who attended outpatient clinics
at Hamamatsu University School of Medicine and 10
related hospitals in Shizuoka Prefecture for routine
check-ups between February and December 2010
were enrolled in this study. All patients satisfied the
definition of asthma of GINA.2 Atopy was defined by
positive specific IgE antibodies to at least one com-
mon inhalant allergen (CAP system; Pharmacia,
Uppsala, Sweden). Inclusion criteria were as follows:
(1) age over 18 years; (2) ability to perform an ade-
quate forced expiratory maneuver; (3) asthma dura-
tion more than 6 months; and (4) receiving SFC 50
250 μg one inhalation bid with or without other medi-
cations for asthma, including leukotriene receptor an-
tagonists, or sustained release theophylline for at
least 8 weeks. Patients were excluded from the study
if they (1) had had any acute viral infections within at
least 1 month before the study; (2) had chronic ob-
structive pulmonary disease; (3) had cardiovascular
diseases; or (4) were pregnant. Peak expiratory flow
(PEF) monitoring was performed in 134 patients us-
ing a Miniwright peak flow meter (Clement Clarke
Int. Ltd, Harlow, UK).
STUDY DESIGN
This was a prospective, multicenter, open-label, un-
controlled longitudinal study. At visit 1, after 8 weeks
of a run-in period, patients completed the Asthma
Control Questionnaire, 5-item version (ACQ5) and
patients with a score of greater than 0.75 were eligi-
ble for this study. SFC was switched to FBC 4.5160
μg two inhalations bid and they attended each hospi-
tal at weeks 4, 8 and 12 of the treatment period, as
shown in Figure 1. The inhaler technique of each pa-
tient was checked appropriately by the involved doc-
tors, nurses, or pharmacists not only during the run-
in period but when switching the regimens and dur-
ing the treatment period. This study was conducted
in accordance with the principles of the Declaration
of Helsinki, the protocols were approved by each lo-
cal ethics committee and informed consent was ob-
tained from all patients prior to the study.
MEASUREMENTS
ACQ5
The ACQ5 (Japanese version) consists of 5 items as-
sessing nocturnal waking, morning symptoms, activ-
ity limitation, shortness of breath, and wheeze during
the previous 7 days, excluding the frequency of short-
acting β2-agonist (SABA) use and FEV1% predicted,
each scored on a scale of 0-6, where 0 represents
good control and 6 represents poor control.8 The
overall score of the ACQ5 is the mean of the five re-
sponses. The cut-point for well-controlled asthma is
less than or equal to 0.75, and a value of greater than
or equal to 1.50 confirms not well-controlled asthma.9
A 0.5 change in each score was considered a clini-
cally meaningful difference, that is, minimum impor-
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Fig.　2　Patient selection. ACQ5, Asthma Control Questionnaire, 5-item version; FBC, 
formoterol/budesonide combination; SFC, salmeterol/fl uticasone combination.
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tant difference (MID).8
Pulmonary Functions
Spirometry was performed at visits 1 and 4 using
computerized equipment (model CHESTAC-8100;
CHEST MI, Inc., Tokyo, Japan). FVC, FEV1, forced
expiratory flow at 50% of FVC (FEF50%), and FEF75%
were expressed as a percentage of predicted values
according to the formula of the Japanese Respiratory
Society.10 In patients who recorded their PEF values
at home, the lowest PEF expressed as a percentage
of the highest PEF (Min%Max PEF) values11 during
the 1-week period prior to examination were calcu-
lated. Patients were requested not to use SABA for at
least 6 h prior to the measurement.
Fractional Exhaled Nitric Oxide (FeNO)
FeNO levels were measured in 97 of 194 patients by
the online method at a flow rate of 50 mlsec using an
NO analyzer (Sievers NOA 280i; GE Analytical Instru-
ments, Boulder, CO, USA) according to the American
Thoracic SocietyEuropean Respiratory Society rec-
ommendations.12
Statistical Analysis
All values are expressed as the means with ranges.
Comparisons between the 2 groups were made using
the unpaired t test and the chi-square or Fisher’s ex-
act test. Paired t test was used to compare changes
between baseline and after switching therapies.
There was no difference in quantitative data and cate-
gorical data between the 97 patients with FeNO data
and the remaining 97 patients without FeNO data by
the t test and the chi-square or Fisher’s exact test, re-
spectively. Stat View Version 5.0 (SAS Institute, Cary,
NC, USA) was used for statistical calculations. A p
value of <0.05 was considered significant, and all tests
were 2 sided.
RESULTS
The patient selection is presented in Figure 2. Of the
194 patients receiving SFC 50250 μg bid and as-
sessed for eligibility, 107 (55.2%) patients with an
ACQ5 score0.75 continued the same treatment regi-
men. The comparison between 107 patients with well-
controlled asthma and the remaining 87 patients with
asthma not adequately controlled is shown in Table 1.
Eighty-seven patients with an ACQ5 score of >0.75
had nonatopic state predominance, lower PEF pa-
rameters and pulmonary functions, longer duration of
treatment with SFC, and more systemic corticoster-
oid use, which were statistically significant.
Of the patients assigned to receive FBC 9320 bid,
4 discontinued because of throat discomfort in 1 and
inability to attend regular check-ups in 3; thus, 83 pa-
tients completed the study. The mean change from
baseline in clinical parameters at the end of treatment
is shown in Table 2 and Figure 3-5. Overall ACQ5
score and each item improved significantly and ex-
ceeded the MID after 12 weeks of treatment. Well-
controlled asthma was attained in 37 (44.6%) patients,
while not well-controlled asthma was reduced to 22
patients. Further, there was a significant improve-
ment in Min and Max PEF and FEV1 values after
Akamatsu T et al.
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Table　1　Characteristics of the study patients
Characteristics ACQ5 ≤0.75(n = 107)
ACQ5 >0.75
(n = 87) p-Value
Age, y 58.1 (20-88) 59.4 (18-85) 0.560
Male/female 52/55 34/53 0.184
Atopic/nonatopic 68/39 45/42 0.037
Non/ex/current smokers 68/35/5 46/35/9 0.150
Duration of asthma, y 14.9 (0.5-75) 12.3 (0.5-50) 0.141
Coexisting nasal diseases 32 20 0.277
Current pet owners 30 14 0.047
Body mass index, kg/m2 22.8 (15.2-34.3) 23.5 (16.2-38.1) 0.297
Total IgE, IU/ml 461 (3-3220) 660 (2-15339) 0.358
ACQ5 overall score 0.19 (0-0.6) 1.63 (0.8-5.0) <0.0001
Min PEF, L/min 362 (126-640) 314 (40-540) 0.020
Max PEF, L/min 405 (130-780) 364 (50-650) 0.0523
Min%Max PEF, % 88.6 (44.4-100) 85.5 (51.7-97.7) 0.033
FVC, L 3.07 (1.57-6.63) 2.68 (0.65-5.48) 0.003
%FVC, % 103.0 (60.1-147.9) 94.7 (28.9-148.4) 0.002
FEV1, L 2.17 (0.76-5.72) 1.86 (0.36-3.69) 0.007
%FEV1, % 85.0 (44.1-167) 80.0 (20.8-140.7) 0.141
%FEF50% 47.9 (7.8-127.2) 50.1 (4.4-175.4) 0.622
%FEF75% 36.3 (8.6-125.0) 34.9 (2.5-146.5) 0.692
FeNO, ppb 39.9 (13.6-197.3) 38.1 (9.8-142.3) 0.865
Duration of treatment with SFC, m 9.6 (2-32) 12.7 (2-34) 0.020
Leukotriene receptor antagonists 41 45 0.061
Sustained-release theophylline 12 17 0.107
Prednisolone  0  4 0.011
Data are expressed as the means with ranges or No.
Abbreviations: ACQ5, Asthma Control Questionnaire, 5-item version; FEF50%, forced expiratory fl ow at 50% of FVC; FeNO, fractional 
exhaled nitric oxide; Max PEF, highest PEF over a week; Min PEF, lowest PEF over a week; Min%Max PEF, lowest PEF over a week ex-
pressed as a percentage of the highest PEF; PEF, peak expiratory fl ow; SFC, salmeterol/fl uticasone combination.
switching from SFC to FBC. FeNO values were meas-
ured in 33 patients and there was no significant
change after switching from SFC to FBC.
DISCUSSION
We assessed the effect of switching from SFC 50250
μg one inhalation bid to FBC 4.5160 μg two inhala-
tions bid in 83 patients with asthma not adequately
controlled under the former treatment regimen. We
demonstrated that ACQ5 scores improved and ex-
ceeded the MID after 12 weeks of treatment and well-
controlled asthma was attained in 37 (44.6%) patients.
We also found that Min and Max PEF and FEV1 val-
ues improved significantly after switching from SFC
to FBC.
Several reports have compared the effect of FBC
and SFC on asthma treatment outcomes; however,
very few have concerned switching treatment regi-
mens. Recently, Hozawa et al.13 reported a study on
the comparison of FBC with SFC on small airway im-
pairment and airway inflammation. After SFC 50250
μg one inhalation bid, patients were randomized into
FBC 4.5160 μg two inhalations bid or continued the
same dose of SFC. They found that patients in the
FBC group showed significant improvement in respi-
ratory mechanics, small airway pulmonary functions,
FeNO values, and ACQ scores compared with the
SFC group. There are several differences in the study
design between Hozawa et al. and the present study,
including no other asthma medications, nonsmokers,
%FEV1 >80%, baseline FeNO levels >35 ppb, and 4
weeks of treatment in their study; however, the effec-
tiveness of switching from SFC to FBC in patients
with asthma not adequately controlled was shown in
the present study as well as in their study.
Possible explanations for the effectiveness of
switching from SFC to FBC are as follows. First, FBC
Turbuhaler particles are smaller than SFC Diskus
particles. The Aerosol Consensus Statement reported
that aerosols with mass median aerodynamic diame-
ters (MMADs) of 2-5 μm are optimal for delivery to
the airways, whereas aerosols with MMADs of 0.8-3.0
μm are suitable for drug delivery to the paren-
chyma.14 Tarsin et al.4 reported that the particle size
Switching ICSLABA Combination Therapy
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Table　2　Mean change from baseline in clinical parameters at the end of treatment
Baseline value Final value p-Value
ACQ5, overall score 1.62 (0.8-5.0) 0.96 (0-3.2) <0.0001
Q1: nocturnal waking 1.23 (0-6) 0.66 (0-4) <0.0001
Q2: morning symptoms 1.53 (0-5) 1.00 (0-4) <0.0001
Q3: activity limitation 1.59 (0-5) 0.87 (0-4) <0.0001
Q4: shortness of breath 1.96 (0-5) 1.22 (0-4) <0.0001
Q5: wheeze 1.80 (0-5) 1.24 (0-5) <0.0001
ACQ5 ≤0.75  0 37
ACQ5 >0.75-<1.50 43 24 <0.0001
ACQ5 ≥1.50 40 22
Min PEF, L/min 319 (40-540) 340 (50-580) 0.0008
Max PEF, L/min 366 (50-650) 377 (50-600) 0.022
Min%Max PEF, % 85.7 (51.7-97.7) 88.6 (60.0-100) 0.065
FVC, L 2.71 (0.65-5.48) 2.77 (0.83-5.56) 0.080
%FVC, % 95.0 (28.9-148.4) 96.9 (37.3-135.6) 0.110
FEV1, L 1.90 (0.36-3.69) 1.97 (0.45-3.75) 0.027
%FEV1, % 79.8 (20.8-140.7) 82.6 (26.3-131.7) 0.040
%FEF50% 51.3 (4.40-175.4) 52.2 (4.43-152.4) 0.633
%FEF75% 35.8 (6.70-146.5) 39.6 (2.39-145.5) 0.128
FeNO, ppb 38.1 (9.8-142.3) 41.6 (11.5-154.2) 0.719
Data are expressed as the means with ranges or No.
Abbreviations: ACQ5, Asthma Control Questionnaire, 5-item version; FEF50%, forced expiratory fl ow at 50% of FVC; FeNO, fractional 
exhaled nitric oxide; Max PEF, highest PEF over a week; Min PEF, lowest PEF over a week; Min%Max PEF, lowest PEF over a week ex-
pressed as a percentage of the highest PEF; PEF, peak expiratory fl ow; SFC, salmeterol/fl uticasone combination.
Fig.　3　Changes in ACQ5 score. The line across the box is 
the median, the top and bottom portions of the box represent 
the 25th and 75th percentiles, respectively, and the whiskers 
indicate the maximum and minimum values at week 0 and 
12. *p < 0.0001. ACQ5, Asthma Control Questionnaire, 
5-item version.
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Fig.　4　Changes in FEV1. The line across the box is the 
median, the top and bottom portions of the box represent the 
25th and 75th percentiles, respectively, and the whiskers in-
dicate the maximum and minimum values at week 0 and 12. 
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Fig.　5　Changes in FeNO. The line across the box is the 
median, the top and bottom portions of the box represent the 
25th and 75th percentiles, respectively, and the whiskers in-
dicate the maximum and minimum values at week 0 and 12. 
FeNO, fractional exhaled nitric oxide.
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of FBC Turbuhaler inspired at a flow rate of 60 lmin
was 2.4 μm for budesonide and 2.5 μm for formoterol,
respectively, while Granlund et al.5 reported that the
particle size of SFC Diskus inspired at a flow rate of
60 lmin was 4.4 μm for both salmeterol and flutica-
sone. These findings suggest that more FBC particles
reached the peripheral airwaysalveolar lesions than
SFC particles, thereby enabling the improvement of
ACQ5 scores and pulmonary functions in the present
study. Secondly, there is a marked difference in in-
trinsic efficacy between formoterol and salmeterol.
Intrinsic efficacy refers to the ability of a drug to acti-
vate its receptor without regard for drug concentra-
tion. Hanania et al. stated in their review that the in-
trinsic efficacy of formoterol is 20% of isoproterenol,
while that of salmeterol is less than 2%.15 Kume16 re-
ported that the values of intrinsic efficacy, expressed
as the maximum percent inhibition for β2-agonists
against 1 μM methacholine-induced contraction in
guinea pig tracheal smooth muscle, were 100% for
formoterol and 62.4% for salmeterol, respectively.
Palmqvist et al.3 found that salmeterol was less effica-
cious for methacholine-induced bronchoconstriction
than formoterol. Thus, the difference in intrinsic effi-
cacy may explain the effectiveness of switching from
SFC to FBC. Thirdly, there is a difference in the on-
set of bronchodilation between FBC and SFC. Studies
have reported that FBC treatment elicited more rapid
onset of bronchodilatory effects than SFC treat-
ment.17 A rapid onset of effect may result in improved
treatment adherence. In a comparison of a fixed-dose
FBC metered-dose inhaler versus a SFC dry powder
inhaler, O’Connor et al.18 found that patients receiv-
ing FBC had more timely relief of symptoms and feel-
ing the medication work right away compared with
those receiving SFC; therefore, the more rapid onset
of the bronchodilatory effects of FBC may lead to im-
provement after switching the treatment regimens.
Concerning the daily ICS doses, SFC 50250 μg
one inhalation bid delivers 500 μg fluticasone
propionate, while FBC 4.5160 μg two inhalations bid
delivers 640 μg budesonide, which is equivalent to
the labeled dose of 800 μg of the same drug. Since
500 μg fluticasone propionate is estimated to be equi-
potent to 800 μg budesonide as a medium daily dose
in GINA 2010,2 we consider that both ICSLABA
combinations are equipotent in the potency of ICS. In
this regard, Japanese Guidelines recommend 400 μg
fluticasone propionate and 800 μg budesonide as me-
dium doses.1 The potency of an ICS may change
when combined with a LABA. Also, the efficacy of
some products varies when administered via different
inhaler devices. Future studies will confirm the clini-
cal relevance of these differences.
There was no effect of switching regimens on
FeNO levels in the present study (from 38.1 ppb to
41.6 ppb). Exhaled NO is the quickest marker to re-
spond to glucocorticoids of asthma control measures,
including symptoms, airflow obstruction, and airway
hyperresponsiveness.19 Gelb et al.20 reported mean
FeNO values of 48 ppb in the 22 patients with clini-
cally stable asthma (more than 8 weeks) on SFC 50
250 μg one inhalation bid more than 1 year. Thus, it
might be possible that FeNO levels had reached a
plateau before switching ICSLABA combinations;
however, there were patients with high levels of
FeNO or not optimally controlled with FBC 4.5160
μg two inhalations bid, suggesting the possibility that
FeNO levels would be reduced by increasing the
FBC doses.
In the present study, we found that 107 of 194
(55.2%) patients receiving SFC 50250 μg one inhala-
tion bid for more than 8 weeks had well-controlled
asthma according to the ACQ5 score, while patients
eligible for the study had nonatopic predominance
and more impaired pulmonary functions. These find-
ings suggest the effectiveness and limitations of a me-
dium daily dose of fluticasone and salmeterol combi-
nation therapy in a real clinical setting. Indeed, it is
thought that SFC 50250 μg is the most useful and
available regimen of the medication, but adequate as-
sessment of asthma control should occasionally be
performed and, if asthma is not optimally controlled,
an increased dose (SFC 50500 μg) or switching
treatment regimens (FBC) are options, although we
cannot recommend which is better at this time. The
present study suggests, at least partly, that a nona-
topic state and impaired pulmonary functions may be
clues to detect patients with asthma not adequately
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controlled, and switching from SFC to FBC is a reli-
able strategy for achieving asthma control.
This was a prospective, multicenter, open-label, un-
controlled longitudinal study. The evidence from an
uncontrolled study is weaker than that from a con-
trolled study, which is the major limitation of the pre-
sent study. The reasons for selecting this type of
study are as follows. First, it is difficult to perform
double blind placebo-controlled trials in Japan with
regard to asthma treatment, including ICS. Secondly,
the protocols should be used for a cross-over study
model to compare the effect of SFC and FBC accu-
rately; however, this was associated with the condi-
tions concerning the asthma medications when the
present study was conducted. SFC had been intro-
duced into Japan more than 2 years before the begin-
ning of the present study and its usefulness in asthma
treatment had been accepted throughout the country,
while FBC had just been introduced. Under such con-
ditions, since we could not collect sufficient patients
receiving FBC, we selected the present study design
to assess the effect of switching from SFC to FBC and
to obtain a sufficient sample size from the multicen-
ters. We preferred a large sample size rather than a
higher evidence level. We also consider that this sim-
ple study design reflects the real clinical setting and
that continuing the same dose of SFC as another arm
was not a genuine control group. Our real intension
lies not in discussing the merits between SFC and
FBC, but in reporting as soon as possible that switch-
ing ICSLABA combination therapy is an important
option in the management of asthma.
In conclusion, switching from SFC 50250 μg one
inhalation bid to FBC 4.5160 μg two inhalations bid
improved the asthma control level and pulmonary
functions in patients with asthma not adequately con-
trolled under the former treatment regimen. Switch-
ing ICSLABA combination therapy is an important
option in the management of asthma.
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